A detailed history of Sei Investments CO transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sei Investments CO holds 9,282 shares of NTLA stock, worth $178,307. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,282
Previous 7,445 24.67%
Holding current value
$178,307
Previous $204,000 1.47%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$20.02 - $27.22 $36,776 - $50,003
1,837 Added 24.67%
9,282 $207,000
Q1 2024

May 07, 2024

BUY
$23.82 - $32.8 $11,195 - $15,415
470 Added 6.74%
7,445 $204,000
Q4 2023

Feb 14, 2024

SELL
$23.16 - $32.34 $28,255 - $39,454
-1,220 Reduced 14.89%
6,975 $212,000
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $15,999 - $23,164
506 Added 6.58%
8,195 $259,000
Q2 2023

Aug 11, 2023

BUY
$34.58 - $46.03 $265,885 - $353,924
7,689 New
7,689 $313,000
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $135,393 - $180,038
2,511 Added 37.34%
9,236 $517,000
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $258,845 - $512,512
6,725 New
6,725 $348,000
Q1 2022

May 13, 2022

SELL
$58.27 - $118.99 $207,732 - $424,199
-3,565 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $998,027 - $1.37 Million
-9,905 Reduced 73.53%
3,565 $422,000
Q3 2021

Nov 12, 2021

SELL
$132.37 - $176.78 $82,201 - $109,780
-621 Reduced 4.41%
13,470 $1.81 Million
Q2 2021

Aug 06, 2021

BUY
$60.88 - $161.91 $857,860 - $2.28 Million
14,091 New
14,091 $2.28 Million
Q4 2018

Feb 13, 2019

SELL
$11.39 - $27.13 $54,045 - $128,731
-4,745 Closed
0 $0
Q3 2018

Nov 08, 2018

SELL
$25.78 - $32.6 $28,899 - $36,544
-1,121 Reduced 19.11%
4,745 $80,000
Q2 2018

Aug 03, 2018

BUY
$20.02 - $30.79 $101,421 - $155,982
5,066 Added 633.25%
5,866 $160,000
Q1 2018

May 11, 2018

BUY
$19.43 - $34.95 $15,544 - $27,960
800 New
800 $17,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.46B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.